Official Journal of Research Center for Gastroenterology and Liver Diseases
Scopus by Title (Ref)
Articles that cite the referenced work, matched by title from the Scopus database.
Cost-of-illness analysis of ulcerative colitis patients treated with biological therapy: a prospective observational study in Iran
BMC Health Services Research
December 2025
Karami H.
Open Access
Societal Economic Burden of Cystic Fibrosis in Iran: A Cost-of-Illness Study
Journal of Health Economics and Outcomes Research
2025
Karami H.
Open Access
Towards hepatitis C virus elimination in Iran: A blueprint for comprehensive strategies
Journal of Viral Hepatitis
September 2024
Mousavi S.F.
Clinical Efficacy and Safety of Direct-Acting Antivirals in Chronic Hepatitis C Treatment: Real-World Data
Viral Hepatitis Journal
December 2023
Doğrugörün A.
Open Access
An Overview of the Action Plans of the Islamic Republic of Iran toward Elimination of Viral Hepatitis B and C
Journal of Mazandaran University of Medical Sciences
May 2023
Bolbanabad A.M.
Economic Burden of Inflammatory Bowel Disease in Shiraz, Iran
Archives of Iranian Medicine
January 2023
Rahmati L.
Open Access
Prevalence of HBV, HCV, and HIV Infections among Patients Undergoing Hemodialysis in Fasa, Iran: A Six-Year Follow-up Study
Middle East Journal of Digestive Diseases
July 2022
Shamsdin S.A.
Open Access
Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS)
BMC Research Notes
December 2021
Mansour-Ghanaei F.
Open Access
Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme
International Journal of Clinical Pharmacy
August 2021
Ali S.
Open Access
Seronegative occult hepatitis C infection among hemodialysis patients: A prevalence study
Therapeutic Apheresis and Dialysis
April 2021
Mahmoudvand S.
Impact of newer direct-acting antiviral drugs based on quality-adjusted life years: A prospective pharmacoeconomic study in hepatitis C patients
Perspectives in Clinical Research
April-June 2021
Vyas B.H.
Open Access
Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review
Pharmacoeconomics
1 September 2020
Mattingly T.J.
Open Access
Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience
Turkish Journal of Gastroenterology
May 2020
Aygen B.
Open Access
Seroepidemiology of hepatitis C among drug users at a detoxification center in Southeast China
Hepatitis Monthly
March 2020
Zhang D.
Open Access
Impact of severity of chronic liver disease on health-related economics
Hepatitis Monthly
2020
Qazi Arisar F.A.
Open Access
Prevalence of hepatitis e virus in thalassemia patients with hepatitis c in Tehran, Iran
Iranian Journal of Microbiology
29 December 2019
Dalvand N.
Open Access
Hepatitis C virus-related policy-making in Iran: A stakeholder and social network analysis
Health Research Policy and Systems
16 April 2019
Behzadifar M.
Open Access
Evaluation of direct acting antivirals efficiency in Turkish patients with chronic hepatitis C under strict rules
Hepatitis Monthly
March 2019
Sarıgul F.
Open Access
The role of insurance providers in supporting treatment and management of hepatitis C patients
BMC Health Services Research
10 January 2019
Behzadifar M.
Open Access
Evaluating the prevalence of HBV, HCV, and HIV in hemodialysis patients in north Cyprus
Hepatitis Monthly
1 January 2019
Güvenir M.
Open Access
Seroepidemiology and risk factors of hepatitis C virus infection in East Azerbaijan, Iran: A population-based Azar Cohort study
Caspian Journal of Internal Medicine
2019
Pouri A.A.
Direct-acting antivirals ombitasvir / paritaprevir / ritonavir + dasabuvir with or without ribavirin in hepatitis C virus (HCV) genotype 1-infected treatment-naive or treatment-experienced patients with or without cirrhosis: Real-life experience in Lithuania and Latvia
Hepatitis Monthly
14 January 2018
Jancoriene L.
Open Access
Non-healthcare costs of hepatitis C: a systematic review
Expert Review of Gastroenterology and Hepatology
2 January 2018
Pascual-Argente N.
MDR1 gene C3435T polymorphism in chronic hepatitis C patients
Microbial Pathogenesis
January 2018
Parsa Nahad M.
Elimination and control of viral hepatitis b and c infections possible with greater attention to high risk groups
Archives of Clinical Infectious Diseases
October 2017
Alavian S.M.
Open Access